Our multidisciplinary team of 40+ experts ensures efficient 360-degree oligonucleotide discovery and development up to IND filing. Leveraging siRNA and ASOs to precisely target RNA and modulate protein expression, we offer state-of-the-art design, synthesis, screening, optimization, early safety and IND enabling toxicology.

Our expertise spans therapeutic areas such as oncology, CNS, and rare diseases. From sequence selection and synthesis to in vitro and in vivo PoC and IND-enabling studies, we guide your program through every crucial stage, providing comprehensive preclinical data and streamlined communication to drive oligonucleotide therapeutics from discovery to clinical success.